Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCorp RxTSXV:PCRX 35 3-1 Month Momentum % is 6.25% as of Aug. 22, 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 671 Healthcare Providers & Services companies, PharmaCorp Rx ranks better than 71.83% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-22), PharmaCorp Rx's 3-1 Month Momentum % is 6.25%.
The industry rank for PharmaCorp Rx's 3-1 Month Momentum % or its related term are showing as below:
TSXV:PCRX's 3-1 Month Momentum % is ranked better than 71.83% of 671
companies
in the Healthcare Providers & Services industry
Industry Median: -1.71
vs TSXV:PCRX: 6.25
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCorp Rx 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where PharmaCorp Rx's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx (TSXV:PCRX) has a 3-1 Month Momentum % of 6.25% as of Aug. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PharmaCorp Rx and its competitors. According to the industry distribution chart, PharmaCorp Rx ranks #189 out of 671 companies in the Healthcare Providers & Services industry, placing it in the top 28.2%.
Is PharmaCorp Rx's 3-1 Month Momentum % too high?
PharmaCorp Rx's current 3-1 Month Momentum % is 6.25%. Based on the distribution chart, PharmaCorp Rx ranks #189 out of 671 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, PharmaCorp Rx has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's 3-1 Month Momentum % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #189 out of 671 companies for 3-1 Month Momentum %. This puts PharmaCorp Rx in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PharmaCorp Rx and its competitors. PharmaCorp Rx's current 3-1 Month Momentum % is 6.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current 3-1 Month Momentum % of 6.25%. The current 3-1 Month Momentum % is 6.25%. PharmaCorp Rx's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current 3-1 Month Momentum % is 6.25% as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
35GF Score
Get the complete analysis for TSXV:PCRX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PCRX has been successfully added to your 
